Business UpdateApr 21, 2026, 08:32 AM
Journey Medical's Emrosi ™ Gains Access to 85% of US Commercial Lives
AI Summary
Journey Medical Corporation announced that its product, Emrosi ™ (40 mg Minocycline Hydrochloride Modified-Release Capsules), has achieved access to approximately 85% of all commercial lives in the United States. This milestone was reached after securing contracts with the three major group purchasing organizations (GPOs). The company anticipates this expanded payer access will drive further growth in total prescription demand and aims to increase health plan formulary adoption to position Emrosi ™ as a standard of care for rosacea, ultimately improving profitability.
Key Highlights
- Emrosi ™ now has access to approximately 85% of all commercial lives in the US.
- This access was achieved after contracting with the third major group purchasing organization (GPO).
- Journey Medical aims to increase formulary adoption nationally and regionally throughout 2026 and beyond.
- The company expects less reliance on co-pay bridging programs and improved profitability for Emrosi ™.
- Emrosi ™ treats inflammatory lesions of rosacea in adults, a condition affecting over 17 million Americans.